<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <meta name="description" content="Latest Parkinson‚Äôs Disease treatments, including stem cell therapies and inflammation reduction.">
  <title>Latest PD Treatments</title>
  <style>
    body {
      font-family: 'Arial', sans-serif;
      background: #fef6f5;
      margin: 0;
      padding: 10px;
      color: #333;
    }
    .container {
      max-width: 1000px;
      margin: 0 auto;
      background: #fff;
      padding: 10px;
      border-radius: 8px;
      box-shadow: 0 2px 8px rgba(0, 0, 0, 0.1);
    }
    h1 {
      text-align: center;
      color: #EF9280;
      margin-bottom: 10px;
      font-size: 24px;
    }
    .home-button {
      display: block;
      text-align: center;
      margin: 10px auto;
      padding: 6px 12px;
      background: #EF9280;
      color: white;
      border: none;
      border-radius: 5px;
      font-size: 14px;
      cursor: pointer;
      text-decoration: none;
      width: 100px;
    }
    .home-button:hover {
      background: #d87a6b;
    }
    .controls {
      display: flex;
      flex-wrap: wrap;
      gap: 8px;
      margin-bottom: 10px;
      justify-content: center;
    }
    select, input, button {
      padding: 6px;
      border: 1px solid #ddd;
      border-radius: 4px;
      font-size: 13px;
      background: #fff;
      box-sizing: border-box;
    }
    select, button {
      width: 130px;
    }
    input {
      flex: 1;
      min-width: 180px;
      padding-right: 64px;
      border: 1px solid #ccc;
    }
    button {
      border: none;
      cursor: pointer;
      background: #EF9280;
      color: white;
    }
    button:hover {
      background: #d87a6b;
    }
    .search-container {
      position: relative;
      flex: 1;
      min-width: 180px;
    }
    .search-container input {
      width: 100%;
      padding-right: 64px;
      height: 30px;
      box-sizing: border-box;
    }
    .search-container #clearBtn,
    .search-container #searchBtn {
      position: absolute;
      top: 0;
      bottom: 0;
      width: 30px;
      display: flex;
      align-items: center;
      justify-content: center;
      font-size: 14px;
      padding: 0;
    }
    .search-container #clearBtn {
      right: 30px;
      background: transparent;
      color: #333;
      border: none;
      cursor: pointer;
      border-right: 1px solid #ddd;
    }
    .search-container #searchBtn {
      right: 0;
      background: #EF9280;
      border: none;
      border-radius: 0 3px 3px 0;
      color: white;
      cursor: pointer;
    }
    .search-container #searchBtn::before {
      content: 'üîç';
    }
    .search-container #clearBtn:hover {
      background: #f0f0f0;
    }
    .table-wrapper {
      overflow-x: auto;
      -webkit-overflow-scrolling: touch;
    }
    table {
      table-layout: fixed;
      width: 100%;
      border-collapse: collapse;
    }
    td, th {
      white-space: normal;
      word-wrap: break-word;
      vertical-align: top;
      padding: 8px;
      border: 1px solid #ccc;
    }
    th {
      background: #EF9280;
      color: white;
      cursor: pointer;
      white-space: nowrap;
    }
    th:hover {
      background: #d87a6b;
    }
    tr:nth-child(even) {
      background: #fff5f3;
    }
    tr:hover {
      background: #ffe6e2;
    }
    a {
      color: #EF9280;
      text-decoration: none;
    }
    a:hover {
      text-decoration: underline;
    }
    th:nth-child(1), td:nth-child(1) { /* Treatment */
      width: 80px;
      overflow: hidden;
      text-overflow: ellipsis;
      white-space: normal;
      word-wrap: break-word;
    }
    th:nth-child(2), td:nth-child(2) { /* Tentative Market Date */
      width: 137px;
      white-space: pre-line; /* Ensure line breaks display */
    }
    th:nth-child(3), td:nth-child(3) { /* Administration */
      width: 108px;
    }
    th:nth-child(4), td:nth-child(4) { /* Goal */
      width: 160px;
      overflow: hidden;
      text-overflow: ellipsis;
      white-space: normal;
      word-wrap: break-word;
    }
    th:nth-child(5), td:nth-child(5) { /* Trial Phase */
      width: 80px;
    }
    th:nth-child(6), td:nth-child(6) { /* Link */
      width: 35px;
    }
    @media (max-width: 600px) {
      th, td {
        font-size: 12px;
        padding: 4px;
      }
      .controls {
        flex-direction: column;
        align-items: stretch;
      }
      select, button {
        width: 100%;
      }
      .search-container {
        min-width: auto;
      }
      .search-container #searchBtn,
      .search-container #clearBtn {
        width: 28px;
      }
      .search-container #clearBtn {
        right: 28px;
      }
      input {
        padding-right: 60px;
      }
    }
  </style>
</head>
<body>
  <div class="container">
    <h1>Aspirationally Aspiring</h1>
    <a href="/" class="home-button">Home</a>
    <div class="controls">
      <div class="search-container">
        <input id="search" type="text" placeholder="Search Treatment...">
        <button id="clearBtn" style="display: none;">‚úï</button>
        <button id="searchBtn"></button>
      </div>
      <select id="sortKey">
        <option value="name">Sort by Treatment</option>
        <option value="tentativeMarketDate">Sort by Tentative Market Date</option>
        <option value="administration">Sort by Administration</option>
        <option value="trialPhase">Sort by Trial Phase</option>
      </select>
      <button id="sortOrder">‚Üì Desc</button>
    </div>
    <div class="table-wrapper">
      <table id="treatmentsTable">
        <thead>
          <tr>
            <th>Treatment</th>
            <th>Tentative Market Date</th>
            <th>Administration</th>
            <th>Goal</th>
            <th>Trial Phase</th>
            <th>Link</th>
          </tr>
        </thead>
        <tbody></tbody>
      </table>
    </div>
  </div>

<script>
const treatments = [
  { id: 1, name: "UDCA", administration: "Oral", goal: "Mitochondrial function", trialPhase: "Phase 2/3", link: "Link", tentativeMarketDate: "2028 Phase 2 positive. Phase 3 planned 2025, market 2028." },
  { id: 2, name: "CDNF", administration: "Intracerebral infusion", goal: "DMT ‚Äì Growth factor infusion for DA neurons", trialPhase: "Phase 2", link: "https://herantis.com", tentativeMarketDate: "Stopped ‚Äì shifted to oral HER-096" },
  { id: 3, name: "PD01A", administration: "Vaccine (subcutaneous)", goal: "DMT ‚Äì Œ±-syn vaccine", trialPhase: "Phase 1 done", link: "https://www.michaeljfox.org", tentativeMarketDate: "Stopped ‚Äì small trials completed, no follow-up" },
  { id: 4, name: "ABL301", administration: "Intravenous (antibody)", goal: "Bispecific antibody targeting aggregated alpha-synuclein and IGF1R for enhanced brain delivery", trialPhase: "Phase 1", link: "Link", tentativeMarketDate: "2032 Phase 1 ongoing. Phase 2 expected 2026, Phase 3 in 2028, market in 2032." },
  { id: 5, name: "P2B001", administration: "Oral", goal: "SMT ‚Äì Combo low-dose pramipexole+rasagiline", trialPhase: "Phase 3", link: "https://clinicaltrials.gov/study/NCT03329508", tentativeMarketDate: "2026 (active; NDA prep after positive Ph3)" },
  { id: 6, name: "NPT088", administration: "IV", goal: "DMT ‚Äì Broad protein clearance (amyloid/Œ±-syn)", trialPhase: "Preclinical in PD", link: "https://www.alzforum.org/therapeutics/npt088", tentativeMarketDate: "Stopped ‚Äì company pivoted to Alzheimer‚Äôs" },
  { id: 7, name: "DNL201", administration: "Oral", goal: "DMT ‚Äì 1st gen LRRK2 inhibitor", trialPhase: "Phase 1", link: "https://denalitherapeutics.com", tentativeMarketDate: "Stopped ‚Äì poor PK/brain penetration" },
  { id: 8, name: "HER-096", administration: "Subcutaneous injection", goal: "Mimic CDNF to provide neuroprotection, promote dopamine neuron survival, reduce Œ±-syn aggregation and neuroinflammation, to slow or halt PD progression", trialPhase: "Phase 1b ongoing (NCT06659562, Parkinson‚Äôs disease patients, 2 doses per week for 4 weeks)", link: "Link", tentativeMarketDate: "2031 Phase 1b topline data expected September 2025. Positive results could lead to Phase 2 in 2026, Phase 3 in 2028, potential market entry in 2031 if successful." },
  { id: 9, name: "VTX3232", administration: "Oral", goal: "NLRP3 inflammasome inhibition to reduce neuroinflammation", trialPhase: "Phase 2a completed, planning Phase 2", link: "Link", tentativeMarketDate: "2032 Phase 2a ongoing, data 2025. Phase 2b 2026, Phase 3 2028, market 2032." },
  { id: 10, name: "VENT-02", administration: "Oral", goal: "DMT ‚Äì NLRP3 inhibitor to slow PD progression", trialPhase: "Phase 1b", link: "https://clinicaltrials.gov/study/NCT06822517", tentativeMarketDate: "Earliest 2030 (active, Phase 1b recruiting)" },
  { id: 11, name: "Inosine", administration: "Oral", goal: "DMT ‚Äì Boosts urate (antioxidant)", trialPhase: "Phase 3", link: "https://pubmed.ncbi.nlm.nih.gov/33914293/", tentativeMarketDate: "Stopped ‚Äì futility + kidney stone risk" },
  { id: 12, name: "GT-02287", administration: "Oral", goal: "Allosteric activator of glucocerebrosidase (GCase) enzyme to restore activity and reduce alpha-synuclein aggregation", trialPhase: "Phase 1b ongoing", link: "Link", tentativeMarketDate: "2030 Phase 1b ongoing. Positive data in 2025 could initiate Phase 2 in 2026, Phase 3 in 2028, market in 2030." },
  { id: 13, name: "Ambroxol", administration: "Oral", goal: "GBA1 enhancer / lysosomal function", trialPhase: "Phase 3", link: "Link", tentativeMarketDate: "2027 Phase 3 ongoing. Data 2025, market 2027 if approved." },
  { id: 14, name: "Imatinib", administration: "Oral", goal: "LRRK2 modulation, autophagy", trialPhase: "Preclinical", link: "Link", tentativeMarketDate: "Unknown Preclinical, early research." },
  { id: 15, name: "Nilotinib", administration: "Oral", goal: "Potential disease-modifying (modulates Œ±-synuclein aggregation, autophagy)", trialPhase: "Phase II ongoing (PD), Phase IIa completed (DLB)", link: "Link", tentativeMarketDate: "2029 Dependent on Phase II/III outcomes and regulatory approval" },
  { id: 16, name: "AAV2-GDNF", administration: "Direct brain injection (gene therapy)", goal: "Deliver GDNF to protect and restore dopaminergic neurons", trialPhase: "Phase 1 completed (safety shown, modest clinical benefit)", link: "Link", tentativeMarketDate: "2030+ Still experimental; more trials needed before approval." },
  { id: 17, name: "Metformin", administration: "Oral", goal: "Mixed data in PD models", trialPhase: "Preclinical / Observational", link: "Link", tentativeMarketDate: "Unlikely Mixed preclinical data, no clear path to approval." },
  { id: 18, name: "Ibuprofen", administration: "Oral", goal: "Neuroprotection potential", trialPhase: "Epidemiology / Preclinical", link: "Link", tentativeMarketDate: "Unknown Preclinical, limited evidence for PD application." },
  { id: 19, name: "Donepezil", administration: "Oral", goal: "SMT ‚Äì Reduce falls/freezing via cholinergic boost", trialPhase: "Phase 2 done", link: "https://pubmed.ncbi.nlm.nih.gov/26879171/", tentativeMarketDate: "Earliest 2028 (completed small trial; no follow-up yet)" },
  { id: 20, name: "Exenatide", administration: "Injection (Subcutaneous)", goal: "Neuroprotection", trialPhase: "Phase 3", link: "Link", tentativeMarketDate: "Unlikely Phase 3 negative, no clear path to approval." },
  { id: 21, name: "Inzomelid", administration: "Oral", goal: "DMT ‚Äì NLRP3 inflammasome inhibitor to reduce neuroinflammation", trialPhase: "Phase 1 completed", link: "https://www.alzforum.org/therapeutics/inzomelid", tentativeMarketDate: "Earliest 2029 (active; next PD trial pending)" },
  { id: 22, name: "Terazosin", administration: "Oral", goal: "Enhances glycolysis", trialPhase: "Preclinical / Observational", link: "Link", tentativeMarketDate: "Unknown Preclinical, observational data only." },
  { id: 23, name: "Tavapadon", administration: "Oral (tablet)", goal: "D1/D5 partial agonist, motor symptom control", trialPhase: "Phase 3", link: "Link", tentativeMarketDate: "2025 Phase 3 positive. Launch 2025." },
  { id: 24, name: "Isradipine", administration: "Oral", goal: "Mitochondrial protection", trialPhase: "Phase 3 completed", link: "Link", tentativeMarketDate: "Unlikely Phase 3 negative, no clear path to approval." },
  { id: 25, name: "Semaglutide", administration: "Injection (Subcutaneous) or Oral", goal: "Neuroprotection", trialPhase: "Preclinical / Early trials", link: "Link", tentativeMarketDate: "2032 Preclinical, early trials. Phase 2 2026, Phase 3 2028, market 2032." },
  { id: 26, name: "Liraglutide", administration: "Injection (Subcutaneous)", goal: "Neuroprotection", trialPhase: "Phase 2 completed", link: "Link", tentativeMarketDate: "2029 Phase 2 completed. Phase 3 2026, market 2029." },
  { id: 27, name: "Propranolol", administration: "Oral (tablet)", goal: "Reduce Parkinsonian tremor via beta-adrenergic blockade", trialPhase: "Repurposed, observational/preclinical", link: "Link", tentativeMarketDate: "Unknown Repurposed, not in formal PD trials." },
  { id: 28, name: "Varenicline", administration: "Oral", goal: "SMT ‚Äì Improve gait/balance via nicotinic receptor stimulation", trialPhase: "Early clinical", link: "https://pubmed.ncbi.nlm.nih.gov/28858562/", tentativeMarketDate: "Stopped ‚Äì small trial done, not pursued" },
  { id: 29, name: "Eltoprazine", administration: "Oral", goal: "SMT ‚Äì 5HT1A/1B agonist; anti-dyskinesia", trialPhase: "Phase 2", link: "https://pubmed.ncbi.nlm.nih.gov/27091431/", tentativeMarketDate: "Earliest 2029 (paused; needs partner)" },
  { id: 30, name: "Lixisenatide", administration: "Injection (Subcutaneous)", goal: "Neuroprotection", trialPhase: "Phase 2", link: "Link", tentativeMarketDate: "2028 Phase 2 positive. Phase 3 planned 2025, market 2028." },
  { id: 31, name: "Pioglitazone", administration: "Oral", goal: "Neuroprotection", trialPhase: "Phase 2 completed", link: "Link", tentativeMarketDate: "Unlikely Phase 2 negative, no clear path to approval." },
  { id: 32, name: "Dapansutrile", administration: "Oral", goal: "DMT ‚Äì NLRP3 inhibitor, targets inflammation", trialPhase: "Phase 2 planned", link: "https://www.isrctn.com/ISRCTN16806940", tentativeMarketDate: "Earliest 2030 (active; Cure Parkinson‚Äôs supported)" },
  { id: 33, name: "ENERGI-F705PD", administration: "Oral, sustained-release tablet", goal: "Enhance cellular ATP and antioxidant production, reduce Œ±-synuclein aggregation, boost tyrosine hydroxylase activity for dopamine synthesis", trialPhase: "Phase 1 completed (healthy volunteers, safety/tolerability), preparing for Phase 2", link: "Link", tentativeMarketDate: "2030 Phase 1 completed. Phase 2 planned 2025, Phase 3 2027, market 2030." },
  { id: 34, name: "Empagliflozin", administration: "Oral", goal: "Neuroprotection", trialPhase: "Preclinical", link: "Link", tentativeMarketDate: "Unknown Preclinical, early research." },
  { id: 35, name: "Exosome Therapy", administration: "Injection (intranasal/intravenous)", goal: "Deliver neuroprotective factors and alpha-synuclein clearance via engineered exosomes", trialPhase: "Preclinical", link: "Link", tentativeMarketDate: "2035 Preclinical now. Market ~2035 if successful." },
  { id: 36, name: "SOD1 modulators", administration: "Injection", goal: "Reduce oxidative stress", trialPhase: "Early research", link: "Link", tentativeMarketDate: "Unknown Preclinical, early research." },
  { id: 37, name: "CREXONT (IPX203)", administration: "Oral (capsule)", goal: "Extended-release carbidopa/levodopa for longer 'on' time", trialPhase: "Phase 3 completed (NCT03877510)", link: "Link", tentativeMarketDate: "2025 NDA submitted, market launch expected 2025." },
  { id: 38, name: "PR001 (LY3884961)", administration: "Intrathecal gene therapy", goal: "DMT ‚Äì GBA gene therapy; restore GCase activity", trialPhase: "Phase 1/2", link: "https://clinicaltrials.gov/study/NCT04127578", tentativeMarketDate: "Earliest 2031 (active; Ph1/2 recruiting)" },
  { id: 39, name: "Copper supplements", administration: "Oral (tablet)", goal: "Restore copper balance, antioxidant effect", trialPhase: "Early research", link: "Link", tentativeMarketDate: "Unknown Preclinical, early research." },
  { id: 40, name: "Levodopa/Carbidopa", administration: "Oral (tablet/capsule)", goal: "Symptom control (dopamine replacement)", trialPhase: "Approved", link: "Link", tentativeMarketDate: "Marketed" },
  { id: 41, name: "RB-190 (metyrosine)", administration: "Oral", goal: "Disease-modifying (reduce dopamine-induced neurotoxicity)", trialPhase: "Preclinical, preparing Phase 2 (IND ready)", link: "Link", tentativeMarketDate: "2032 Phase 1 planned. Phase 2 2026, Phase 3 2028, market 2032." },
  { id: 42, name: "NE3107 (Bezisterim)", administration: "Oral (tablet)", goal: "Reduce neuroinflammation, early therapy", trialPhase: "Phase 2", link: "Link", tentativeMarketDate: "2029 Phase 2 ongoing. Phase 3 2026, market 2029." },
  { id: 43, name: "CRISPR Gene Editing", administration: "Gene editing (in vivo/ex vivo)", goal: "Correct PD-causing mutations (e.g., LRRK2, SNCA) with precision editing", trialPhase: "Preclinical", link: "Link", tentativeMarketDate: "2035+ Preclinical only, years from market." },
  { id: 44, name: "UCB0022 (Glovadalen)", administration: "Oral", goal: "Symptom control via D‚ÇÅ receptor positive allosteric modulation", trialPhase: "Phase 1 completed, Phase 2 ongoing (ATLANTIS)", link: "Link", tentativeMarketDate: "2028 Phase 2 completed. Phase 3 expected 2025, market 2028." },
  { id: 45, name: "RB-190 (roscovitine)", administration: "Oral", goal: "LRRK2 kinase inhibition", trialPhase: "Phase 1", link: "Link", tentativeMarketDate: "2032 Phase 1. Phase 2 2026, Phase 3 2028, market 2032." },
  { id: 46, name: "AAV2-hAADC (VY-AADC)", administration: "Intracranial gene therapy", goal: "SMT ‚Äì Improve levodopa conversion via AADC enzyme boost", trialPhase: "Phase 1b/2", link: "https://clinicaltrials.gov/study/NCT01973543", tentativeMarketDate: "Stopped ‚Äì strategic shift (Voyager/Neurocrine)" },
  { id: 47, name: "Rapamycin (Sirolimus)", administration: "Oral", goal: "Autophagy activator", trialPhase: "Preclinical / Early PD studies", link: "Link", tentativeMarketDate: "2032 Preclinical, early studies. Phase 1/2 2026, Phase 3 2028, market 2032." },
  { id: 48, name: "TED-A9 (S. Biomedics)", administration: "Cell infusion", goal: "iPSC-derived dopaminergic progenitors to restore dopamine neurons", trialPhase: "Phase 1/2a ongoing (NCT05565962)", link: "Link", tentativeMarketDate: "2030 Phase 1/2a ongoing. Phase 3 ~2027, market ~2030." },
  { id: 49, name: "NouvNeu 001 (iRegene)", administration: "Cell infusion", goal: "Chemically induced iPSC-derived dopaminergic progenitors for neuron replacement", trialPhase: "Phase 1/2 ongoing (NCT06167681)", link: "Link", tentativeMarketDate: "2031 Phase 1/2 ongoing. Phase 3 ~2027, market ~2031." },
  { id: 50, name: "Solangepras (CVN-424)", administration: "Oral", goal: "SMT ‚Äì GPR6 inverse agonist; improves motor and possibly cognitive function", trialPhase: "Phase 3", link: "https://clinicaltrials.gov/study/NCT06553027", tentativeMarketDate: "2027 (active; Ph3 ongoing, readout 2026)" },
  { id: 51, name: "Minzasolmin (UCB0599)", administration: "Oral", goal: "DMT ‚Äì Œ±-syn misfolding inhibitor", trialPhase: "Phase 2", link: "https://www.ucb.com", tentativeMarketDate: "Stopped ‚Äì failed Ph2 (no benefit)" },
  { id: 52, name: "Sunrise-PD (ulotaront)", administration: "Oral", goal: "Non-motor symptoms", trialPhase: "Phase 2", link: "Link", tentativeMarketDate: "2029 Phase 2. Phase 3 2026, market 2029." },
  { id: 53, name: "BIIB122 (DNL151) ‚Äî LUMA", administration: "Oral (tablet)", goal: "LRRK2 inhibitor aiming to slow progression in early Parkinson‚Äôs disease", trialPhase: "Phase 2b active, not recruiting (NCT05348785)", link: "Link", tentativeMarketDate: "2029‚Äì2030 If Phase 2b is positive, Phase 3 would be required; earliest launch late 2020s." },
  { id: 54, name: "Dipraglurant (ADX48621)", administration: "Oral", goal: "SMT ‚Äì mGluR5 inhibitor; reduce dyskinesia", trialPhase: "Phase 2a done", link: "https://www.addextherapeutics.com", tentativeMarketDate: "Earliest 2029 (awaiting funding/partner for Ph2b)" },
  { id: 55, name: "GZ/SAR402671 (Venglustat)", administration: "Oral (tablet)", goal: "Target GBA mutation, slow progression", trialPhase: "Phase 2", link: "Link", tentativeMarketDate: "Discontinued Phase 2 negative, no further development." },
  { id: 56, name: "Accordion Pill (AP-CD/LD)", administration: "Oral", goal: "SMT ‚Äì Extended levodopa delivery", trialPhase: "Phase 3", link: "https://pubmed.ncbi.nlm.nih.gov/32315722/", tentativeMarketDate: "Stopped ‚Äì failed Ph3 efficacy" },
  { id: 57, name: "REGENERATE-PD (Gene therapy)", administration: "Intracerebral injection", goal: "Gene therapy to regenerate dopaminergic function and restore motor control", trialPhase: "Preclinical", link: "Link", tentativeMarketDate: "2035 Preclinical, early-stage. Market ~2035 if successful." },
  { id: 58, name: "ANPD001 (Aspen Neuroscience)", administration: "Cell infusion (autologous)", goal: "Autologous iPSC-derived dopamine neurons to restore dopaminergic function", trialPhase: "Phase 1/2a ongoing (NCT06381864)", link: "Link", tentativeMarketDate: "2031 Phase 1/2a ongoing, market 2031 if successful." },
  { id: 59, name: "Bemnapredocel (cell therapy)", administration: "Cell infusion", goal: "Replace lost dopamine neurons", trialPhase: "Phase 1/2", link: "Link", tentativeMarketDate: "2028 Phase 1 positive. Phase 3 2025, market 2028." },
  { id: 60, name: "Apomorphine (Onapgo, Apokyn)", administration: "Oral film, sublingual", goal: "Reduce 'off' episodes", trialPhase: "Approved", link: "Link", tentativeMarketDate: "Marketed" },
  { id: 61, name: "XS-411 (XellSmart Biomedical)", administration: "Cell infusion", goal: "Allogeneic iPSC-derived dopaminergic neuron precursors for Parkinson‚Äôs treatment", trialPhase: "Phase 1 ongoing", link: "Link", tentativeMarketDate: "2032 Phase 1 ongoing. Phase 2 ~2026, Phase 3 ~2029, market ~2032." },
  { id: 62, name: "Alpha-synuclein immunotherapy", administration: "Injection/Infusion", goal: "Remove toxic alpha-synuclein", trialPhase: "Phase 2/3", link: "Link", tentativeMarketDate: "2028 Phase 2/3 ongoing. Phase 3 2025, market 2028." },
  { id: 63, name: "RNDP-001 (Kenai Therapeutics)", administration: "Cell infusion", goal: "Allogeneic iPSC-derived dopaminergic progenitors for Parkinson‚Äôs treatment", trialPhase: "Preclinical, IND planned", link: "Link", tentativeMarketDate: "2034 Preclinical now. Phase 1 ~2026, market ~2034." },
  { id: 64, name: "TFG 001 (TreeFrog Therapeutics)", administration: "Cell infusion", goal: "Scalable iPSC-derived dopaminergic neuron therapy for PD", trialPhase: "Preclinical, Phase 1 planned for 2027", link: "Link", tentativeMarketDate: "2035 Preclinical now. Phase 1 ~2027, market ~2035." },
  { id: 65, name: "ICA07 (iCamuno Biotherapeutics)", administration: "Cell infusion", goal: "iPSC-derived dopaminergic precursors to replace lost neurons", trialPhase: "Phase 1 ongoing", link: "Link", tentativeMarketDate: "2032 Phase 1 ongoing. Market ~2032 if successful." },
  { id: 66, name: "Prasinezumab (RO7046015/PRX002)", administration: "IV", goal: "DMT ‚Äì Anti-Œ±-syn antibody to block spread", trialPhase: "Phase 3 starting", link: "https://www.roche.com/media/releases/med-cor-2025-06-16", tentativeMarketDate: "2030 (active; moving into Ph3 despite Ph2b miss)" },
  { id: 67, name: "Peroneal eTNM¬Æ (URIS I‚Ñ¢ device)", administration: "Home-based (30 min daily, non-invasive neuromodulation)", goal: "Reduce tremor and improve quality of life as an add-on therapy", trialPhase: "Pilot study completed; 24-month follow-up (NCT06570421) ongoing", link: "Link", tentativeMarketDate: "2031 Early clinical stage, pending larger RCTs." },
  { id: 68, name: "Buntanetap / Posiphen / ANVS-401", administration: "Oral tablet", goal: "Reduce the production of multiple neurotoxic proteins, including Œ±-synuclein, tau, and amyloid precursor protein, to slow or halt Parkinson‚Äôs disease progression and improve both motor and cognitive symptoms", trialPhase: "Phase 3 completed (NCT05357989, early-stage PD, 10 mg & 20 mg daily dosing)", link: "Link", tentativeMarketDate: "2027 Phase 3 completed. NDA planned for 2026, potential approval and market entry in 2027." },
  { id: 69, name: "Fetal/Embryonic Stem Cell Grafts", administration: "Cell infusion", goal: "Replace dopamine neurons with fetal/embryonic stem cell-derived neurons", trialPhase: "Historical/limited trials", link: "Link", tentativeMarketDate: "Unlikely Ethical and sourcing challenges limit future use." },
  { id: 70, name: "LRRK2 inhibitors (DNL151/BIIB122)", administration: "Oral (tablet)", goal: "Slow progression in LRRK2 mutation carriers", trialPhase: "Phase 3", link: "Link", tentativeMarketDate: "2028 Phase 2/3 ongoing. Phase 3 data 2025, market 2028." },
  { id: 71, name: "UX-DA001 (Shanghai Yuesai Biotech)", administration: "Cell infusion", goal: "iPSC-derived dopaminergic progenitors for neuronal replacement", trialPhase: "Phase 1 planned (China)", link: "Link", tentativeMarketDate: "2033 Phase 1 ~2025, Phase 2 ~2027, Phase 3 ~2030, market ~2033." },
  { id: 72, name: "Nicotinamide Riboside (NR, NOPARK)", administration: "Oral", goal: "Disease-modifying (NAD‚Å∫ replenishment, neuroprotection)", trialPhase: "Phase 1 completed, Phase 2/3 ongoing (NOPARK)", link: "Link", tentativeMarketDate: "2029 Phase 2 ongoing. Phase 3 2026, market 2029." },
  { id: 73, name: "CT1-DAP001 (Sumitomo Pharma / CiRA)", administration: "Cell infusion", goal: "Allogeneic iPSC-derived dopaminergic progenitor cells for neuron replacement", trialPhase: "Phase 1/2 ongoing (NCT04651873)", link: "Link", tentativeMarketDate: "2030 Phase 1/2 ongoing. Phase 3 ~2027, market ~2030." },
  { id: 74, name: "Extended-release Levodopa/Carbidopa", administration: "Oral (tablet/capsule)", goal: "Reduce 'off' time, improved symptom control", trialPhase: "Approved", link: "Link", tentativeMarketDate: "Marketed" },
  { id: 75, name: "Bemdaneprocel (BlueRock Therapeutics)", administration: "Cell infusion", goal: "Replace lost dopamine neurons with iPSC-derived midbrain dopaminergic neurons", trialPhase: "Phase 2 ongoing (NCT04802733)", link: "Link", tentativeMarketDate: "2030 Phase 2 ongoing. Phase 3 planned 2027, market 2030." },
  { id: 76, name: "Oryon Cell Therapies (autologous iPSC)", administration: "Cell infusion (autologous)", goal: "Patient-specific iPSC-derived dopaminergic neurons to restore striatal dopamine", trialPhase: "Phase 1 ongoing (Australia)", link: "Link", tentativeMarketDate: "2032 Phase 1 ongoing. Market ~2032 if successful." },
  { id: 77, name: "NN-9001 (Novo Nordisk / Lund University)", administration: "Cell infusion", goal: "Stem-cell derived dopaminergic neurons for neuron replacement", trialPhase: "Phase 1 ongoing (NCT05114617)", link: "Link", tentativeMarketDate: "2031 Phase 1 ongoing. Phase 3 ~2028, market ~2031." 
];

// DOM elements
const searchInput = document.getElementById('search');
const searchBtn = document.getElementById('searchBtn');
const clearBtn = document.getElementById('clearBtn');
const sortKey = document.getElementById('sortKey');
const sortOrderBtn = document.getElementById('sortOrder');
const tableBody = document.getElementById('treatmentsTable').querySelector('tbody');

// State
let currentSortKey = 'name';
let currentSortOrder = 'asc';
let currentSearch = '';

// Helper: Parse market date for sorting
function parseMarketDate(val) {
  if (!val) return Infinity;

  // Extract the first line (before \n)
  const firstLine = val.split('\n')[0].trim();

  // Handle special cases
  if (firstLine === "Marketed") return -Infinity; // Sort first
  if (firstLine === "Unlikely" || firstLine === "Unknown" || firstLine === "Discontinued") return Infinity; // Sort last

  // Parse numeric year (e.g., "2027")
  const year = parseInt(firstLine, 10);
  if (!isNaN(year)) return year;

  // Fallback for any unexpected format
  return Infinity;
}

// Render table
function renderTable() {
  let filtered = treatments.filter(t =>
    t.name.toLowerCase().includes(currentSearch.toLowerCase())
  );

  filtered.sort((a, b) => {
    if (currentSortKey === 'tentativeMarketDate') {
      const aDate = parseMarketDate(a.tentativeMarketDate);
      const bDate = parseMarketDate(b.tentativeMarketDate);
      return currentSortOrder === 'desc' ? bDate - aDate : aDate - bDate;
    }
    // All others compared as strings (case-insensitive)
    return currentSortOrder === 'desc'
      ? String(b[currentSortKey]).localeCompare(String(a[currentSortKey]))
      : String(a[currentSortKey]).localeCompare(String(b[currentSortKey]));
  });

  tableBody.innerHTML = '';
  filtered.forEach(t => {
    const row = document.createElement('tr');
    row.innerHTML = `
      <td>${t.name}</td>
      <td>${t.tentativeMarketDate}</td>
      <td>${t.administration}</td>
      <td>${t.goal}</td>
      <td>${t.trialPhase}</td>
      <td><a href="${t.link}" target="_blank">Link</a></td>
    `;
    tableBody.appendChild(row);
  });

  // Keep sort button label in sync after each render
  sortOrderBtn.textContent = currentSortOrder === 'desc' ? '‚Üì Desc' : '‚Üë Asc';
}

function updateSearch() {
  currentSearch = searchInput.value;
  clearBtn.style.display = searchInput.value ? 'flex' : 'none';
  renderTable();
}

searchInput.addEventListener('input', updateSearch);
searchBtn.addEventListener('click', updateSearch);

clearBtn.addEventListener('click', () => {
  searchInput.value = '';
  currentSearch = '';
  clearBtn.style.display = 'none';
  renderTable();
});

sortKey.addEventListener('change', e => {
  currentSortKey = e.target.value;
  renderTable();
});

// Sort order button toggles direction
sortOrderBtn.addEventListener('click', () => {
  currentSortOrder = currentSortOrder === 'desc' ? 'asc' : 'desc';
  renderTable();
});

// Initial: Sync button text and render
sortOrderBtn.textContent = currentSortOrder === 'desc' ? '‚Üì Desc' : '‚Üë Asc';
renderTable();
</script>
</body>
</html>
